Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CDK2 inhibitor NKT3447

An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon oral administration, CDK2 inhibitor NKT3447 selectively targets, reversibly binds to and inhibits the activity of CDK2. This blocks G1/S cell cycle transition, which leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDK2, a serine/threonine kinase that plays an important role in the regulation of cell cycle progression and cellular proliferation, is overexpressed in certain tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	NKT 3447 NKT-3447 NKT3447

CDK2 inhibitor NKT3447

Search NCI's Drug Dictionary